NO20004169D0 - Midler til behandling av lidelser som stammer fra narkotikamisbruk - Google Patents

Midler til behandling av lidelser som stammer fra narkotikamisbruk

Info

Publication number
NO20004169D0
NO20004169D0 NO20004169A NO20004169A NO20004169D0 NO 20004169 D0 NO20004169 D0 NO 20004169D0 NO 20004169 A NO20004169 A NO 20004169A NO 20004169 A NO20004169 A NO 20004169A NO 20004169 D0 NO20004169 D0 NO 20004169D0
Authority
NO
Norway
Prior art keywords
pct
abuse
drug
treatment
sec
Prior art date
Application number
NO20004169A
Other languages
English (en)
Other versions
NO20004169L (no
NO318461B1 (no
Inventor
Anders Bjoerk
Gunnar Andersson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20004169L publication Critical patent/NO20004169L/no
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of NO20004169D0 publication Critical patent/NO20004169D0/no
Publication of NO318461B1 publication Critical patent/NO318461B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO20004169A 1992-04-21 2000-08-21 Midler til behandling av lidelser som stammer fra narkotikamisbruk NO318461B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201239A SE9201239D0 (sv) 1992-04-21 1992-04-21 Agents for treating substance abuse disorders
PCT/SE1993/000339 WO1993020821A1 (en) 1992-04-21 1993-04-19 Agents for treating substance abuse disorders

Publications (3)

Publication Number Publication Date
NO20004169L NO20004169L (no) 1994-10-20
NO20004169D0 true NO20004169D0 (no) 2000-08-21
NO318461B1 NO318461B1 (no) 2005-03-21

Family

ID=20386004

Family Applications (2)

Application Number Title Priority Date Filing Date
NO943977A NO308827B1 (no) 1992-04-21 1994-10-20 Midler til behandling av lidelser som stammer fra narkotikamisbruk
NO20004169A NO318461B1 (no) 1992-04-21 2000-08-21 Midler til behandling av lidelser som stammer fra narkotikamisbruk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO943977A NO308827B1 (no) 1992-04-21 1994-10-20 Midler til behandling av lidelser som stammer fra narkotikamisbruk

Country Status (26)

Country Link
US (1) US5565455A (no)
EP (1) EP0637242B1 (no)
JP (1) JP3245642B2 (no)
KR (1) KR100321319B1 (no)
AT (1) ATE184484T1 (no)
AU (1) AU659941B2 (no)
BG (1) BG62154B1 (no)
BR (1) BR9306361A (no)
CA (1) CA2118512C (no)
CZ (1) CZ281296B6 (no)
DE (1) DE69326459T2 (no)
DK (1) DK0637242T3 (no)
EE (1) EE02974B1 (no)
ES (1) ES2139007T3 (no)
GR (1) GR3032030T3 (no)
HU (1) HU223463B1 (no)
IL (1) IL105449A (no)
NO (2) NO308827B1 (no)
PH (1) PH31051A (no)
RO (1) RO117150B1 (no)
RU (1) RU2126254C1 (no)
SE (1) SE9201239D0 (no)
SK (1) SK279940B6 (no)
UA (1) UA27884C2 (no)
WO (1) WO1993020821A1 (no)
ZA (1) ZA932757B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
SE9601708D0 (sv) 1996-05-06 1996-05-06 Pharmacia Ab Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
KR100607838B1 (ko) 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
RU2215527C2 (ru) * 2001-09-28 2003-11-10 Областная наркологическая больница Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2958694A (en) * 1959-06-22 1960-11-01 Janssen Paul Adriaan Jan 1-(aroylalkyl)-4-(2'-pyridyl) piperazines
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
US2979508A (en) * 1959-10-12 1961-04-11 Paul A J Janssen Heterocyclic derivatives of 1-phenyl-omega-(piperazine) alkanols
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
US5217987A (en) 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
SE9201239D0 (sv) 1992-04-21
RU2126254C1 (ru) 1999-02-20
CA2118512A1 (en) 1993-10-28
RO117150B1 (ro) 2001-11-30
NO20004169L (no) 1994-10-20
KR100321319B1 (ko) 2002-07-27
IL105449A (en) 1998-02-22
AU659941B2 (en) 1995-06-01
CZ281296B6 (cs) 1996-08-14
WO1993020821A1 (en) 1993-10-28
UA27884C2 (uk) 2000-10-16
SK279940B6 (sk) 1999-06-11
DE69326459D1 (de) 1999-10-21
ES2139007T3 (es) 2000-02-01
NO318461B1 (no) 2005-03-21
US5565455A (en) 1996-10-15
EE02974B1 (et) 1997-04-15
JPH08503449A (ja) 1996-04-16
NO308827B1 (no) 2000-11-06
JP3245642B2 (ja) 2002-01-15
EP0637242B1 (en) 1999-09-15
HU223463B1 (hu) 2004-07-28
KR950701221A (ko) 1995-03-23
EP0637242A1 (en) 1995-02-08
HU9403020D0 (en) 1994-12-28
PH31051A (en) 1998-02-03
DE69326459T2 (de) 2000-03-23
GR3032030T3 (en) 2000-03-31
RU94045866A (ru) 1996-10-20
ATE184484T1 (de) 1999-10-15
NO943977D0 (no) 1994-10-20
SK126994A3 (en) 1995-07-11
AU4043793A (en) 1993-11-18
ZA932757B (en) 1993-10-28
BR9306361A (pt) 1998-06-30
CZ260694A3 (en) 1995-09-13
HUT71420A (en) 1995-11-28
DK0637242T3 (da) 2000-03-27
CA2118512C (en) 2004-07-27
BG62154B1 (bg) 1999-04-30
IL105449A0 (en) 1993-08-18
BG99129A (bg) 1995-08-28
NO943977L (no) 1994-10-20

Similar Documents

Publication Publication Date Title
NO20004169L (no) Midler til behandling av lidelser som stammer fra narkotikamisbruk
EP0722941A3 (en) Compounds having effects on serotonin-related systems
PT100279A (pt) Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega
PT751766E (pt) Administracao nasal e ocular de cetamina para gerir a dor e para desintoxicacao
Coccaro Psychopharmacological studies in patients with personality disorders: Review and perspective.
AU2018792A (en) Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
ATE74271T1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
Wilbur et al. Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
FI951683L (fi) Yhdisteiden, joilla on antiglukokortikoidiaktiivisuus, käytt¦ sellaisten lääkkeiden valmistamiseksi, jotka on tarkoitettu huumausaineiden tai huumausaineseosten spontaaniin tai laukaistuun vieroitusoireyhtymäänliittyvien oireiden estämiseen tai hoitoon, ja niitä sisältäviä
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
Castleden et al. Increased sensitivity to benzodiazepines in the elderly
NO943293L (no) Anvendelse av et medikament ved avvenning mot röyk
Weiss et al. Adenosine antagonists: lack of effect on the inhibition of kindled seizures in rats by carbamazepine
Matalon et al. Chronic use of hypnotics in a family practice—patients' reluctance to stop treatment
Wheatley Transdermal nitroglycerin in angina pectoris
Baughman The safety record of buspirone in generalized anxiety disorder.
WO1997028823A1 (en) Method of using antacid agent and pharmaceutical preparation containing antacid agent
Richmond et al. Controlled Trial of the 24-Hour Transdermal Nicotine Patch in Conjunction With Cognitive-Behavioural Therapy: 6-Months’ Results
ATE147980T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triaz nisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
KR900017583A (ko) 경구용 진해 조성물
Grinspoon 22. Cocaine
BAHNA Long term detoxification of rehabilitated methadone patients
Sagduyu One personal copy may be printed
KR910005868A (ko) 신규 치료법

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees